Pharma BD Deal Intelligence
Alexion's $1.41B Portola buy at a 132% premium bought Andexxa, the only approved Factor Xa reversal agent—but Elliott Management publicly slammed it as value-destructive, and andexanet never approached blockbuster status, peaking near $219M globally in 2024.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →The U.S. Food and Drug Administration today granted accelerated approval to Andexxa (coagulation factor Xa [recombinant], inactivated-zhzo), the first and only…
Alexion Pharmaceuticals said on Tuesday it would buy Portola Pharmaceuticals for about $1.41 billion to add the only approved reversal agent for the side…
Atrial fibrillation affects an estimated 6 million people in the United States, with prevalence projected to rise to over 12 million by 2030. AF increases…
Source summaries from our enrichment pipeline; follow links for originals.
All 18 sources with sentiment breakdown →
Alexion acquired Portola Pharmaceuticals for $18.00/share in cash, ~$1.41B total; announced May 5, 2020 and completed July 2, 2020 via tender offer (~79.7% of shares tendered) and back-end merger. The deal added Andexxa/Ondexxya (andexanet alfa), the only approved reversal agent for Factor Xa inhibitors (Eliquis, Xarelto), expanding Alexion beyond Soliris into hematology. Activist investor Elliott Management publicly criticized the deal as value-destructive. The thesis ultimately did not hold: andexanet never approached its projected blockbuster sales (peaking near $219M globally in 2024, only ~$81M of it US). Alexion itself was acquired by AstraZeneca (completed July 2021), folding Andexxa into AstraZeneca Rare Disease. The ANNEXA-I confirmatory randomized trial (2024) met its hemostasis endpoint (63.9% vs 52.4% good/excellent hemostasis) but showed materially higher thrombosis (14.6% vs 6.9%) and thrombosis-related deaths. In December 2025 AstraZeneca voluntarily withdrew Andexxa's US biologics license application effective Dec 22-23, 2025 after the FDA concluded its serious thromboembolic risks outweighed its benefit and a path from conditional to traditional approval could not be reached.
Assessment window: 5yr post-close.
200K US cases/yr · $450M Andexxa global net sales 2019 (USD MM, Portola 10-K) · 112 Andexxa Q1 2020 net product revenue (USD MM)
Major bleeding on Factor Xa (FXa) inhibitors — apixaban (Eliquis), rivaroxaban (Xarelto), edoxaban (Savaysa) and historic enoxaparin — is a sizable acute-care problem. Approximately 8 million US patients are on direct oral anticoagulants (DOACs) at any time for atrial fibrillation, VTE prevention/treatment and post-orthopedic surgery prophylaxis, with FXa inhibitors representing ~85% of the DOAC market by 2020 (Eliquis alone surpassed $9B global net product revenue in 2019). The annual incidence of major bleeding on DOACs runs 2-3.5% per year, translating to roughly 150,000-250,000 US events annually, of which intracranial hemorrhage (ICH) and gastrointestinal bleeds dominate hospital encounters and carry 30-day mortality of 20-50% in ICH. Before andexanet alfa (Andexxa, ANNEXA-4 cohort), no specific reversal agent existed for FXa inhibitor-associated bleeds; standard of care was off-label four-factor prothrombin complex concentrate (Kcentra, FEIBA) or supportive transfusion. Andexxa received FDA accelerated approval May 2018 for apixaban/rivaroxaban reversal and EMA conditional marketing authorization (Ondexxya) April 2019. Despite strong clinical pull, Andexxa adoption was hampered by hospital pricing (~$25-50K per dose), guideline ambiguity and the absence of confirmatory mortality data — the post-marketing ANNEXA-I trial was running at deal date.
At deal date, Andexxa/Ondexxya was the only FDA/EMA-approved specific reversal agent for FXa inhibitors and held effective monopoly in the indication. Direct anticoagulant reversal competition: Boehringer Ingelheim's idarucizumab (Praxbind) reverses dabigatran (a direct thrombin inhibitor, NOT FXa) — approved 2015, ~$200M global sales 2019. Off-label and emerging FXa-reversal alternatives included ciraparantag (Perosphere/AMAG, universal anticoagulant antidote, Phase 3 paused after Phase 2 in 2019, later acquired by Alnylam-spinout pivotal in 2024), and four-factor PCCs (CSL Behring Kcentra, Takeda Beriplex, Octapharma Octaplex) used off-label per ACC/AHA 2017 guidelines. The underlying anticoagulant landscape itself was concentrated: BMS/Pfizer apixaban (Eliquis, $9.2B 2019), J&J/Bayer rivaroxaban (Xarelto, $7.6B 2019), Daiichi Sankyo edoxaban (Savaysa). Portola's adjacent pipeline included cerdulatinib (an oral SYK/JAK inhibitor in Phase 2 for relapsed peripheral T-cell lymphoma) and Bevyxxa (betrixaban, an oral FXa inhibitor for VTE prophylaxis in acute medically ill patients) — Bevyxxa was discontinued April 2020 weeks before the Alexion deal due to commercial underperformance.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Alexion Pharmaceuticals Inc. / Portola Pharmaceuticals, Inc. (this deal) | 2020 | $1.4B | — |
| Alexion Pharmaceuticals Inc. / Synageva BioPharma | 2015 | $8.4B | 36 |
| Alexion Pharmaceuticals Inc. / Wilson Therapeutics AB | 2018 | $855M | 20 |
| Alexion Pharmaceuticals Inc. / Syntimmune, Inc. | 2018 | $1.2B | 14 |
| Alexion Pharmaceuticals Inc. / Achillion Pharmaceuticals, Inc. | 2019 | $1.2B | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
← Browse all deals · How we score deals
More: 2020 deals · Alexion Pharmaceuticals Inc. deals · Hematology deals